Swedish Ski Team's Novo Nordisk Sponsorship Sparks Ethical Debate in Norway

The Swedish ski team's recent decision to partner with Novo Nordisk, a company known for its weight loss drug Ozempic, has stirred significant controversy and criticism in Norway. Experts and prominent figures within Norwegian sports circles have expressed strong disapproval, warning about the ethical implications of promoting medications linked to weight loss within a sporting context. Petter S Skinstad, a TV2 Norway ski expert, condemned the partnership as "very bad," questioning why the successful Swedish ski federation chose to associate with such a sponsor. Moreover, Lars Engebretsen, head of WADA's health and research team, highlighted health risks associated with these drugs and advocated for a ban on their use in sports, noting reports of athletes using them during the recent Paris Olympics. Norwegian ski champion Therese Johaug echoed concerns about the negative signals this sponsorship could send to young athletes who look up to elite competitors. Jorunn Sundgot-Borgen, a sports medicine professor, described the sponsorship as "very, very unfortunate," cautioning it might normalize the use of weight loss medications among youth athletes. Swedish ski stars have largely avoided direct commentary, some offering vague responses that indicate unease. This controversy raises broader questions about doping ethics and the messaging sports organizations send to the next generation of athletes.